Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) released its quarterly earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11), Briefing.com reports. The business had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The company’s revenue was up 65.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.18) EPS.

Kiniksa Pharmaceuticals Trading Up 3.4 %

NASDAQ:KNSA opened at $17.68 on Wednesday. The firm has a market capitalization of $1.25 billion, a PE ratio of 98.23 and a beta of 0.27. The stock has a 50 day moving average of $19.36 and a 200-day moving average of $18.00. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $22.09.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on KNSA shares. Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday. TheStreet raised Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a report on Thursday, February 29th.

Insider Activity

In other news, CAO Michael R. Megna sold 5,126 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Michael R. Megna sold 5,126 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Michael R. Megna sold 9,659 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $377,262.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,109 shares of company stock valued at $709,929. 54.23% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.